Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-07
2006-02-07
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S114000, C544S127000, C544S362000, C514S233800, C514S253030
Reexamination Certificate
active
06995171
ABSTRACT:
The invention relates to compounds of the formulas 1 and 2and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein X, R1and R11are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1 and 2 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas 1 and 2.
REFERENCES:
patent: 4710506 (1987-12-01), Davies et al.
patent: 5587458 (1996-12-01), King et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Begley et al.
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 5877305 (1999-03-01), Huston et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 6071935 (2000-06-01), Lyssikatos
patent: 6225318 (2001-05-01), Sobolov-Jaynes et al.
patent: 6284764 (2001-09-01), Kath et al.
patent: 6465449 (2002-10-01), Kath et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 0239362 (1991-12-01), None
patent: 606046 (1994-07-01), None
patent: 780386 (1997-06-01), None
patent: 0818442 (1998-01-01), None
patent: 931788 (1999-07-01), None
patent: 952148 (1999-10-01), None
patent: 1044578 (2000-05-01), None
patent: 1081138 (2001-03-01), None
patent: WO 90/05719 (1990-05-01), None
patent: WO 95/19774 (1995-07-01), None
patent: WO 95/19970 (1995-07-01), None
patent: WO 95/21613 (1995-08-01), None
patent: WO 95/23141 (1995-08-01), None
patent: WO 96/27583 (1996-09-01), None
patent: WO 96/30347 (1996-10-01), None
patent: WO 96/33172 (1996-10-01), None
patent: WO 96/40142 (1996-12-01), None
patent: WO 97/13760 (1997-04-01), None
patent: WO 97/13771 (1997-04-01), None
patent: WO 97/22596 (1997-06-01), None
patent: WO 97/32856 (1997-09-01), None
patent: WO 97/49688 (1997-12-01), None
patent: WO 98/02434 (1998-01-01), None
patent: WO 98/02437 (1998-01-01), None
patent: WO 98/02438 (1998-01-01), None
patent: WO 98/03516 (1998-01-01), None
patent: WO 98/07697 (1998-02-01), None
patent: WO 98/14451 (1998-04-01), None
patent: WO 98/23613 (1998-06-01), None
patent: WO 98/30566 (1998-07-01), None
patent: WO 98/33768 (1998-08-01), None
patent: WO 98/34915 (1998-08-01), None
patent: WO 98/34918 (1998-08-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 98/54093 (1998-12-01), None
patent: WO 99/07675 (1999-02-01), None
patent: WO 99/10349 (1999-03-01), None
patent: WO 99/16755 (1999-04-01), None
patent: WO 99/24440 (1999-05-01), None
patent: WO 99/29667 (1999-06-01), None
patent: WO 99/35132 (1999-07-01), None
patent: WO 99/35146 (1999-07-01), None
patent: WO 99/52889 (1999-10-01), None
patent: WO 99/52910 (1999-10-01), None
patent: WO 99/61422 (1999-12-01), None
patent: WO 99/62890 (1999-12-01), None
patent: WO 00/74681 (2000-12-01), None
patent: WO 00/38665 (2001-07-01), None
Compounds with RN 65075-96-9 and RN 99429-85-3.
Barker, John M., et al., “Thienopyridines. Part 5. Carbon-13 N.m.r. Spectra of Some Thieno[3,2-b]pyridines, and Some Further Transformations in the Series,”J. Chem. Research, 1984, 84-85.
Barker, John M., et al., “Thienyl Analogues of the Alkaloids. Part 3. Analogues of Echinorine and Echinopsine; a Convenient Synthesis of Thieno[3,2-b]pyridines,”J. Chem. Research, 1978, 393.
Cao, Y., et al., “Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor”,J. Biol. Chem., 1996, 3154-3162, vol. 271, No. 6.
Corbett, T.H., et al., “A Mouse Colon-tumor Model for Experimental Therapy,”Cancer Chemotherapy Reporter(Part 2)., 1975, 169-186, vol. 5.
Corbett, T.H., et al., “Tumor Induction Relationships in Development of Transplantable Cancers of the Colon in Mice for Chemotherapy Assays, with a Note on Carcinogen Structure,”Cancer Research, 1975, 2434-2439, vol. 35.
Fleisher, et al., “Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs,”Advanced Drug Delivery Reviews, 1996, 115-130, vol. 19.
Furniss, B.S., et al.,Vogel's Textbook of Practical Organic Chemistry, Fifth Edition, 1996, Longman, Harlow, England.
Geran, R.I., et al., “Protocols for Screening Chemical Agents and Natural Products Aganist Animal Tumors and Other Biological Systems,”Cancer Chemotherapy Reporter, Third Edition, 1972, pp. 1-104, vol. 3.
Gill, G.N., et al., “[7] Purification of Functionally Active Epidermal Growth Factor Receptor Protein Using a Competitive Antagonist Monoclonal Antibody and Competitve Elution with Epidermal Growth Factor,”Methods in Enzymology, 1987, 82-86, vol. 146.
Greene, T.W., et al.,Protective Groups in Organic Synthesis, Second Edition, 1991, John Wiley & Sons, New York.
Katritzky, et al.,Comprehensive Heterocyclic Chemistry II, 1996, vols. 5, 6 and 7, Elsevier Science Ltd., Oxford.
Klemm, L.H., et al., “Chemistry of Thienopyridines. XXIV. Two Transformations of Thieno [2,3-b]pyrimidine 7-Oxide (1),”J. Heterocyclic Chem., 1976, 1197-1200, vol. 13.
Miyaura, et al., “Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds,”Chem. Rev., 1995, 2457-2483, vol. 95.
Posner, et al., “Kinetic Model of the Epidermal Growth Factor (EGF) Receptor Tyrosine Kinase and a Possible Mechanism of Its Activation by EGF,”Journal of Biological Chemistry, 1992, 20638-20647, vol. 267, No. 29.
Remington, et al.,Remington's Pharmaceutical Sciences, 15thEd., 1975, Mack Publishing Co., Easter, PA.
Robinson, et al., “Discovery of the Hemifumarate and (α-L-Alanyloxy)methyl Ether as Prodrugs of Antirheumatic Oxindole: Prodrugs for the Enolic OH Group,”J. Med. Chem., 1996, 10-18, vol. 39, No. 1.
Sumpter, et al., “Hetercyclic Compounds with Indole and Carbazole Systems,”The Chemistry of Heterocyclic Compounds, 1954, Interscience Publishers, New York.
Waltenberger, et al., “Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor,”J. Biol. Chem., 1994, 26988-26995, vol. 269, No. 43.
Autry Christopher
Luzzio Michael J.
Marx Matthew A.
Agouron Pharmaceuticals , Inc.
Aulakh Charanjit S.
Pugmire Matthew J.
Zielinski Bryan C.
LandOfFree
Bicyclic pyrimidine and pyrimidine derivatives useful as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic pyrimidine and pyrimidine derivatives useful as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic pyrimidine and pyrimidine derivatives useful as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3686944